Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project

Sant, Milena; Allemani, Claudia; Ţereanu, Carmen; Angelis, Roberta De; Capocaccia, Riccardo; Visser, Otto; Marcos‐Gragera, Rafael; Maynadié, Marc; Simonetti, A; Lutz, Jean-Michel; Berrino, Franco

doi:10.1182/blood-2010-05-282632

Cited by 771 publications

(610 citation statements)

References 20 publications

Supporting

Mentioning

513

Contrasting

Unclassified

Order By: Relevance

“…In this study, the total incidence rate of leukemia (Myeloid and Lymphoid) is obtained 2.4 per 100,000 annually and incidence rate of lymphoma (HD and NHL) is obtained 3.5 per 100,000, while the incidence rate of leukemia in the world have estimated 10 per 100,000 (Sant et al, 2010;Goldman et al, 2012). Non-Hodgkin's Lymphoma has the highest annual incidence rate (2.5 per 100,000) and Hodgkin's disease has the lowest annual incidence rate (1 per 100,000) (Ansel and Armitage, 2006;Punnett et al, 2010).…”

Section: Gendermentioning

confidence: 70%

“…Non-Hodgkin's Lymphoma has the highest annual incidence rate (2.5 per 100,000) and Hodgkin's disease has the lowest annual incidence rate (1 per 100,000) (Ansel and Armitage, 2006;Punnett et al, 2010). The incidence rate of Acute Myeloid Leukemia is 2.3 per 100,000 and the incidence rate of Chronic Myeloid Leukemia is 1-1.3 per 100,000 (Baccaraniet al, 2009;Dohner et al, 2010;Sant et al, 2010) but in this study, the annually incidence rate of Myeloid leukemia (acute and chronic) is obtained 1.1 per 100,000.…”

Section: Gendermentioning

confidence: 99%

See 1 more Smart Citation

Blood Malignancies in Mazandaran Province of Iran

Tahmasby

Marnani²,

Maleki³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: Leukemia and lymphoma demonstrate significantly incidence rates throughout the world and particularly in Iran they cause serious mortality and diagnosis and treatment expenditures for both families and the health system. Combined they account for about 11 percent of cancers in Mazandaran province, ranking number 2 in prevalent cancers. The purpose of this study was to provide a first general and specific description of leukemia and lymphoma in Mazandaran province. Materials and Methods: In this descriptive retrospective study, entire patient's data were reviewed which had confirmed diagnosis of leukemia and lymphoma with valid laboratory or pathology reports in the period 2001-2008. The data were collected by Babol health research site related to Tehran University of Medical Science. Incidence rates based on age groups, gender, city of residence and type of malignancy were calculated and analyzed. Results: In Mazandaran province, 1,146 cases of leukemia and lymphoma were encountered, 5.9 in 100,000 persons on average annually. The highest incidence rates were obtained at age of 70 or above (26.4) and the lowest at age of 0-9 (2.3).The incidence rates in males and females were 7.1 and 4.8 respectively with a ratio of 1.5. The highest incidence rate was in Babol (7.3) and the lowest was calculated in Neka and Tonekabon equally (1.5). According to the type of malignancy, non Hodgkin lymphoma, with 2.5/100,000 have the most incidence rate and myeloid leukemia with 1.8 had the lowest. Conclusions: The obtained findings indicate clear differences in incidence rates based on age, gender, residence, and type of malignancy. Therefore it's suggested that in addition to promote data collecting programs, research projects should be programmed to define leukemia and lymphoma risk factors in this province.

show abstract

Section: Gendermentioning

confidence: 70%

Section: Gendermentioning

confidence: 99%

Blood Malignancies in Mazandaran Province of Iran

Tahmasby

Marnani²,

Maleki³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…Similar studies in USA concerning blood cancer in Europe and USA in 2005 showed that overall incidences for hematopoietic malignancies have been raised along western countries and AML incidence had slow decrease or stable trend in the most European countries but it has been surged in Wales and England about 70% from 1971 for both sexes (Rodriguez-Abreu et al, 2007). Also researches have shown that different blood cancer incidence are higher among men (than women) which is comparable in the countries including Iran, Kazakhstan, Croatia, European union and United states (Coebergh et al, 2006;Tahmasebi et al, 2006;Rodriguez-Abreu et al, 2007;Hejazi et al, 2010;Sant et al, 2010;Dastgiri et al, 2011;Farahmand et al, 2011;Modak et al, 2011;Smith et al, 2011;Dores et al, 2012;Novak et al, 2012;Rajabli et al, 2013) and higher incidence among men may be attributed to genetically or environmental factors (Rajabli et al, 2013;Igissinov et al, 2014).…”

Section: Discussionmentioning

confidence: 99%

“…Studies around the world show that blood malignancy incidence is increased by age (Coebergh et al, 2006;Sant et al, 2010;Dores et al, 2012;Novak et al, 2012). Performed studies in Iran confirm increasing trend of blood cancer incidence by age increase so that age groups higher than 70 years old has the most incidence rate (Tahmasebi et al, 2006).…”

Section: Introductionmentioning

confidence: 99%

“…Performed studies in Iran confirm increasing trend of blood cancer incidence by age increase so that age groups higher than 70 years old has the most incidence rate (Tahmasebi et al, 2006). Studies in Iran and other countries have shown that blood malignancies incidence is higher among men than women (Tahmasebi et al, 2006;Sant et al, 2010;Zand et al, 2010;Dores et al, 2012;Novak et al, 2012; Howlader N NA, based on November 2013 SEER data submission, posted to the SEER web site, April 2014).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Leukemia in Iran: Epidemiology and Morphology Trends

Koohi

Salehiniya²,

Shamlou³

et al. 2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: Leukemia accounts for 8% of total cancer cases and involves all age groups with different prevalence and incidence rates in Iran and the entire world and causes a significant death toll and heavy expenses for diagnosis and treatment processes. This study was done to evaluate epidemiology and morphology of blood Statistical analysis for incidence time trends and morphology change percentage was performed with joinpoint regression analysis using the software Joinpoint Regression Program. Results: During the studied years a total of 18,353 hematopoietic and reticuloendothelial system cancers were recorded. Chi square test showed significant difference between sex and morphological types of blood cancer (P-value<0.001). Joinpoint analysis showed a significant increasing trend for the adjusted standard incidence rate (ASIR) for both sexes (P-value<0.05). Annual percent changes (APC) for women and men were 18.7 and 19.9, respectively. The most common morphological blood cancers were ALL, ALM, MM and CLL which accounted for 60% of total hematopoietic system cancers. Joinpoint analyze showed a significant decreasing trend for ALM in both sexes (P-value<0.05). Conclusions: Hematopoietic system cancers in Iran demonstrate an increasing trend for incidence rate and decreasing trend for ALL, ALM and CLL morphology.

show abstract